AnaptysBio, Inc. (ANAB) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.38B USD. 52-week range 20.18 to 72.36 USD. Data as of 2026-10-09.
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc ...